UK healthtech startups are having a defining moment. Britain is now the most active healthtech market in Europe, and a run of large rounds in 2025 and 2026 has pushed money into AI diagnostics, virtual wards, drug discovery and NHS-integrated care platforms. For founders, investors and operators tracking the sector, the interesting question is no longer whether UK healthtech can raise, but which companies are turning funding into real NHS deployments and revenue. Below are the UK healthtech startups worth watching, grouped by what they actually do, with the funding and NHS traction to back it up.
Why UK healthtech is pulling in the money
The pitch for UK healthtech is simple: a single national health system, strong university research, and a growing willingness inside the NHS to buy from startups rather than only from incumbents. A new generation of companies is moving from pilots to live deployments, backed by NHS AI Award funding or direct contracts with trusts and integrated care boards. That shift from proof-of-concept to paid, scaled use is what separates the names below from the hype. The UK digital health market is now valued at around $18bn, and by late 2024 domestic health-tech companies had raised more than £27bn in total capital, a base the 2025 and 2026 rounds are building on.
AI diagnostics: catching disease earlier
TidalSense, based in Cambridge, has built an AI-driven respiratory diagnostic that reads a patient’s breathing pattern to assess lung disease. Its technology aims to cut the time to a chronic obstructive pulmonary disease (COPD) assessment from around an hour to a few minutes, and the company raised roughly $19m in 2026 to push into routine respiratory care. Faster, cheaper triage for lung conditions is exactly the kind of measurable win the NHS will pay for.
Kheiron Medical Technologies, headquartered in London, developed Mia, an AI tool that flags suspicious lesions on screening mammograms. Mia was evaluated under the NHS AI in Health and Care Award and has been used within NHS breast-screening services including NHS Grampian and the EMRAD imaging network, with the goal of catching cancers earlier while reducing unnecessary recalls. It is one of the clearer examples of British medical AI reaching real clinical pathways.
Virtual wards and home care: moving the hospital home
Doccla runs “virtual wards” that let patients be monitored at hospital-level from home using a pre-configured tablet and wearable devices. The London company raised a £35m Series B in late 2024 to expand across Europe, and in 2025 NHS Greater Glasgow and Clyde began building a 1,000-bed virtual ward using its technology. Doccla has reported outcomes such as a 29% reduction in emergency admissions within one integrated care board, the sort of hard number that wins repeat NHS contracts.
Cera is a London-based, digital-first home healthcare business that combines carers, nurses and software to deliver and predict care needs in people’s homes. It raised around $150m in 2025 and is one of the largest UK healthtech companies by headcount, positioning home care as a way to keep patients out of hospital beds altogether.
AI drug discovery: the sector’s biggest bet
The standout raise belongs to Isomorphic Labs, the London drug-design company spun out of Google DeepMind. Building on AlphaFold 3, the protein-structure model it released with DeepMind in 2024, Isomorphic raised $600m in its first external round in early 2025, then a $2.1bn Series B in 2026 led by Thrive Capital. That is the largest bet yet on AI-led drug discovery anywhere, and it anchors the UK’s claim to lead the field. Because the sum dwarfs every other round in the sector, we have left it off the chart above so the mid-market raises stay legible.
Digital health platforms and clinical trials
Evaro, a Norwich-based, NHS-licensed digital healthcare platform, secured a EUR21m Series A in 2026 to expand its API-first infrastructure and embedded clinical services. 01Health, in London, raised a EUR12.9m Series A the same year to bring specialist diagnostics and care from private clinics to the high street. And Lindus Health, another London company, is rebuilding the contract research organisation model for clinical trials; it raised a $55m Series B in 2025 led by Balderton, taking total funding above $80m.
The risks behind the headlines
For all the momentum, UK healthtech is not an easy sell. NHS procurement is slow and fragmented across dozens of trusts and integrated care boards, so a contract in one region does not automatically scale to the next. Regulation is strict, and any tool that influences diagnosis or treatment needs clinical evidence and, often, medical-device approval. Cash-strapped trusts also want proof of savings, not just better outcomes. The companies most likely to endure are those that can show a clear return on investment, clear regulation early, and build a product that deploys the same way in Grampian as it does in Greater Manchester. Anyone reading the sector should weigh deployment breadth and evidence as heavily as headline round sizes.
What to watch next
The pattern across these UK healthtech startups is consistent: the winners pair a credible clinical claim with a route into NHS budgets, whether through the AI Award, virtual-ward funding or direct trust contracts. For investors and founders, the signals to track are live deployments and repeat orders rather than pilot announcements, published outcome data, and whether a company can scale across integrated care boards without rebuilding its product each time.
Frequently asked questions
What counts as a healthtech startup?
Healthtech covers companies using technology to improve how care is delivered, diagnosed, funded or managed. In the UK that spans AI diagnostics, remote monitoring and virtual wards, digital-first care providers, drug discovery and the data and trials infrastructure behind them.
Which UK healthtech startup has raised the most?
Isomorphic Labs, the DeepMind drug-discovery spinout, raised a $2.1bn Series B in 2026, by far the largest UK healthtech round and one of the biggest in AI drug discovery globally.
How do healthtech startups sell to the NHS?
Routes include the NHS AI in Health and Care Award, framework agreements, and direct contracts with individual trusts or integrated care boards. Companies usually start with an evaluation or pilot, then scale if they can show clinical and financial benefit.
Is the UK a good place to build a healthtech company?
It has clear advantages: a single national health system as a reference customer, strong research universities, and record investment. The challenge is long NHS sales cycles and strict regulation, so founders need patience and clinical evidence, not just a product.
Why does AI dominate UK healthtech funding?
Investors see AI as the fastest route to measurable savings, whether that is quicker diagnosis, fewer hospital admissions or cheaper drug discovery. The biggest 2025-26 rounds all had an AI angle, from imaging and respiratory diagnostics to protein modelling.
For more on the UK startup and funding landscape, visit IDEA London. Details of how the NHS backs early-stage medical technology are published by the NHS AI Lab.